Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus

BMC Nephrology

Thomas Sciascia³  Howard Hait²  Carey Hines⁴  Jolene Berg⁵  Harry Alcorn⁵  Amale Hawi¹ 

[1] A Hawi Consulting, Ridgefield, CT, USA;Edenridge Associates LLC, Wilmington, DE, USA;Trevi Therapeutics, 195 Church Street, 14th Floor, New Haven 06510, CT, USA;PPD, Richmond, VA, USA;DaVita Clinical Research, Minneapolis, MN, USA

关键词: Itch;    Nalbuphine;    Safety;    Pruritus;    Pharmacokinetics;    Opioid;    Hemodialysis;    ESRD;   

Others  :  1161099
DOI  :  10.1186/s12882-015-0043-3

 received in 2014-08-15, accepted in 2015-03-31,  发布年份 2015

【 摘 要 】

Background

Uremic pruritus is a common and deleterious condition among hemodialysis (HD) patients. Central gating of μ/κ opiate circuitry plays an important role in mediating and countering pruritogenic sensation. The objective of this study was to assess the safety and pharmacokinetics (PK) of the mixed μ-antagonist/κ-agonist nalbuphine, administered orally as nalbuphine HCl extended release (ER) tablets in HD patients, and explore its effect on pruritus.

Methods

In this open-label multiple escalating dose study, 15 HD patients with pruritus and 9 matched healthy subjects were enrolled. Nalbuphine HCl ER dose was escalated from 30 mg QD to 240 mg BID over 15 days. A full PK profile was obtained under dialysis and non-dialysis conditions as a function of dose. Clearance during dialysis was determined by sampling dialysate and arterial/venous blood during dialysis. Pruritus severity was assessed twice daily using a Visual Analog Scale (VAS). Safety monitoring included extensive monitoring of EKG, blood pressure, and pulse oximetry.

Results

In HD patients, nalbuphine concentration peaked within 4–9 hours and attained steady state within 2–3 days, with no significant accumulation. Mean half-life was 14.2 hours, mean C_max and AUC_tau ranged between 13 and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion. Exposure in HD patients was about 2-fold higher than in healthy subjects. There was no meaningful difference between exposure on dialysis and non-dialysis days with 1% or less of the dose removed by dialysis. Nalbuphine suppressed itch in a dose-dependent manner, reducing mean VAS score from 4.0 to 1.2 at 180 mg and 0.4 at 240 mg.

Conclusions

Nalbuphine HCl ER tablets can be safely administered to HD patients without dose adjustment up to 240 mg BID and may hold promise in treating uremic pruritus.

【 授权许可】

   
2015 Hawi et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, Smith M, et al.: A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5(8):1410-9.
• [2]Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, et al.: Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006, 21(12):3495-505.
• [3]Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al.: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006, 69(9):1626-32.
• [4]Manenti L, Tansinda P, Vaglio A: Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs 2009, 69(3):251-63.
• [5]Mettang M, Weisshaar E: Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Lett 2010, 15(2):1-5.
• [6]Mettang T, Kremer AE: Uremic pruritus. Kidney Int 2014. Jan 8. doi:10.1038/ki.2013.454.
• [7]Legroux-Crespel E, Cledes J, Misery L: A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004, 208(4):326-30.
• [8]Patel TS, Freedman BI, Yosipovitch G: An update on pruritus associated with CKD. Am J Kidney Dis 2007, 50(1):11-20.
• [9]Paus R, Schmelz M, Biro T, Steinhoff M: Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006, 116(5):1174-86.
• [10]Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, et al.: Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003, 477(1):29-35.
• [11]Kumagai H, Saruta T, Matsukawa S, Utsumi J: Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritus. In Itch, Basic Mechanisms and Therapy. Marcel Dekker Inc, New York; 2004.
• [12]Pan ZZ: mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998, 19(3):94-8.
• [13]Schmelz M: Itch and pain. Dermatol Ther 2005, 18(4):304-7.
• [14]Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H: Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010, 25(4):1251-7.
• [15]Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al.: Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005, 16(12):3742-7.
• [16]Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al.: Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996, 348(9041):1552-4.
• [17]Gutstein H, Akil H: Chapter 23: Opioid analgesics. In The pharmacologic basis of therapeutics. 10th edition. McGraw Hill, New York, NY; 2001:599.
• [18]Nalbuphine HCl Injection Solution. Labelling Information, Hospira, Inc. Lake Forest, IL. October 2007.
• [19]Cohen SE, Ratner EF, Kreitzman TR, Archer JH, Mignano LR: Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesth Analg 1992, 75(5):747-52.
• [20]Liao CC, Chang CS, Tseng CH, Sheen MJ, Tsai SC, Chang YL, et al.: Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after cesarean delivery. Chang Gung Med J 2011, 34(2):172-8.
• [21]Wang JJ, Ho ST, Hu OY: Comparison of intravenous nalbuphine infusion versus saline as an adjuvant for epidural morphine. Reg Anesth 1996, 21(3):214-8.
• [22]Wang JJ, Ho ST, Tzeng JI: Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects. Reg Anesth Pain Med 1998, 23(5):479-84.
• [23]Wittels B, Glosten B, Faure EA, Moawad AH, Ismail M, Hibbard J, et al.: Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: maternal outcomes. Anesth Analg 1993, 77(5):925-32.
• [24]Hawi A, Hunter R, Morford L, Sciascia T: Nalbuphine attenuates itch in the Substance-P induced mouse model. Acta Derm Venereol 2013, 93:S634.
• [25]Johnson SJ. Opioid safety in patients with renal or hepatic dysfunction. In: Pain Treatment Topics. 2007. http://paincommunity.org/blog/wp-content/uploads/Opioids-Renal-Hepatic-Dysfunction.pdf.
• [26]Mercadante S, Arcuri E: Opioids and renal function. J Pain 2004, 5(1):2-19.
• [27]Smith HS: Opioid metabolism. Mayo Clin Proc 2009, 84(7):613-24.
• [28]Aitkenhead AR, Lin ES, Achola KJ: The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. Br J Clin Pharmacol 1988, 25(2):264-8.
• [29]Jaillon P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, et al.: Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. Clin Pharmacol Ther 1989, 46(2):226-33.
• [30]Errick JK, Heel RC: Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1983, 26(3):191-211.
• [31]Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG: Nalbuphine. Drug Alcohol Depend 1985, 14(3–4):339-62.